Investor sentiment toward Pfizer remains cautious despite a significant development in its dermatology pipeline. The pharmaceutical giant announced accelerated plans for a promising new skin treatment, but this positive news was immediately clouded by a clinical trial failure in its critical oncology division, sending shares lower.
Oncology Partnership Hits a Roadblock
The primary driver behind the stock’s negative reaction was a simultaneous announcement from Pfizer’s partner, Roche. The companies reported that their joint Phase 3 trial, named “persevERA,” did not achieve its primary endpoint. This study was evaluating Roche’s investigational drug, Giredestrant, in combination with Pfizer’s established breast cancer therapy, Ibrance. The combination therapy failed to demonstrate a statistically significant improvement in progression-free survival for patients compared to the current standard of care.
This disappointment in the lucrative cancer drug sector effectively overshadowed all other updates. Following the news, Pfizer’s stock declined, closing at 22.99 euros. The share price is now approaching its 200-day moving average of 21.64 euros. With a Relative Strength Index (RSI) reading of 21.6, the stock is considered technically oversold in the short term, reflecting the current pessimistic mood among investors.
A Bright Spot in Immunology
Separately, Pfizer delivered encouraging data from its immunology research. A Phase 2 study for its trispecific antibody, Tilrekimig, showed significant efficacy in treating patients with moderate-to-severe atopic dermatitis. The drug, designed to block three distinct inflammatory pathways, successfully met its primary endpoint.
Should investors sell immediately? Or is it worth buying Pfizer?
After a 16-week treatment period, patients experienced a marked improvement in their skin condition. The placebo-adjusted response rates for achieving a 75% skin improvement ranged from approximately 39% to 52%, depending on the dosage administered. Given these positive results and a favorable tolerability profile, Pfizer is moving quickly to advance the program. The company now plans to initiate the pivotal Phase 3 clinical trial by the end of 2026, aiming to address the high unmet medical need for this chronic skin disease more rapidly.
Looking Ahead: A Pivotal Milestone on the Horizon
Despite the headwinds from the oncology setback, the progress with Tilrekimig strengthens Pfizer’s strategic position in the high-growth market for inflammatory diseases. The next major catalyst for this asset is now clearly defined: the launch of the Phase 3 trial scheduled for late 2026. The outcome of this final-stage study will ultimately determine the commercial potential of this new dermatological treatment.
For now, the market’s reaction underscores a familiar dynamic in biopharma investing: setbacks in core therapeutic areas like cancer can readily dampen enthusiasm for progress elsewhere in a company’s portfolio.
Ad
Pfizer Stock: Buy or Sell?! New Pfizer Analysis from March 10 delivers the answer:
The latest Pfizer figures speak for themselves: Urgent action needed for Pfizer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 10.
Pfizer: Buy or sell? Read more here...
